1378388-19-2

Basic information

• Product Name: 7-[(2-Bromo-5-chlorophenyl)methoxy]-3,4-dihydro-1(2H)-naphthalenone
• Synonyms: 7-[(2-Bromo-5-chlorophenyl)methoxy]-3,4-dihydro-1(2H)-naphthalenone;7-((2-Bromo-5-chlorobenzyl)oxy)-3,4-dihydronaphthalen-1(2H)-one;CL122
• CAS NO: 1378388-19-2
• Molecular Formula: C₁₇H₁₄BrClO₂
• Molecular Weight: 365.64886
• Mol File: 1378388-19-2.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 489.4±45.0 °C(Predicted)
• Appearance: /
• Density: 1.488±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 7-[(2-Bromo-5-chlorophenyl)methoxy]-3,4-dihydro-1(2H)-naphthalenone(CAS DataBase Reference)
• NIST Chemistry Reference: 7-[(2-Bromo-5-chlorophenyl)methoxy]-3,4-dihydro-1(2H)-naphthalenone(1378388-19-2)
• EPA Substance Registry System: 7-[(2-Bromo-5-chlorophenyl)methoxy]-3,4-dihydro-1(2H)-naphthalenone(1378388-19-2)

Safety Data

• Hazardous Substances Data: 1378388-19-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
BNTX is utilized as a κ-opioid receptor antagonist for the study and treatment of pain and addiction. Its selectivity allows it to block the effects of opioid drugs without impacting the analgesic properties of non-opioid pain medications, offering a potential advantage in managing opioid dependence and abuse.
Used in Neurological Disorders Research:
In the field of neurological disorders, BNTX is used as a research tool to explore the role of the κ-opioid receptor system in conditions such as depression and anxiety. Its modulation of this receptor system suggests potential therapeutic applications in treating these disorders, providing a new avenue for intervention and management strategies.
Used in Drug Development:
BNTX serves as a lead compound in drug development for the creation of novel medications targeting the κ-opioid receptor. Its unique properties make it a valuable asset in the design of new therapies aimed at addressing unmet needs in pain, addiction, and mental health treatment.

Upstream product

• 66192-24-3 2-bromo-5-chlorobenzyl bromide 
• 22009-38-7 7-hydroxy-1-tetralone 

Downstream Products

• 1378390-29-4 3-(2-bromoacetyl)-10,11-dihydro-5H-dibenzo[c,g]chromen-8(9H)-one 
• 1378390-35-2 (2S,5S)-2-(2-(9-bromo-8-oxo-8,9,10,11-tetrahydro-5H-dibenzo[c,g]chromen-3-yl)-2-oxoethyl) 1-tert-butyl 5-methylpyrrolidine-1,2-dicarboxylate 
• 1378390-69-2 (2S,4S)-2-(2-(9-bromo-8-oxo-8,9,10,11-tetrahydro-5H-dibenzo[c,g]chromen-3-yl)-2-oxoethyl) 1-tert-butyl 4-methylpyrrolidine-1,2-dicarboxylate 
• 1378391-42-4 (2S,4S)-2-(2-(9-bromo-8-oxo-8,9,10,11-tetrahydro-5H-dibenzo[c,g]chromen-3-yl)-2-oxoethyl) 1-tert-butyl 4-(methoxymethyl)pyrrolidine-1,2-dicarboxylate 
• 1378391-43-5 (2R,4R)-1-tert-butyl 2-(2-(9-((2S,5S)-1-((S)-2-(methoxycarbonylamino)-3-methylbutanoyl)-5-methylpyrrolidine-2-carbonyloxy)-8-oxo-8,9,10,11-tetrahydro-5H-dibenzo[c,g]chromen-3-yl)-2-oxoethyl) 4-(methoxymethyl)pyrrolidine-1,2-dicarboxylate 
• 1378388-20-5 3-chloro-10,11-dihydro-5H-benzo[d]naphtho[2,3-b]pyran-8(9H)-one 
• 1378391-38-8 3-(2-bromo-1-hydroxyethyl)-10,11-dihydro-5H-dibenzo[c,g]chromen-8(9H)-one 

Relevant articles and documents

Compound used for inhibiting hepatitis C virus, and pharmaceutical applications thereof

The invention relates to a compound which is represented by formula I, is used for inhibiting hepatitis C virus, and possesses excellent bioavailability, and a nontoxic pharmaceutically acceptable salt thereof. The compound possesses extremely high inhibition effect on HCV of all genotypes. In the formula I, R is used for representing hydrogen atom, glycyl, L-alanyl, L-leucyl, L-valyl, or L-isoleucyl.

Deuterated antiviral active compounds for hepatitis C viruses

The invention relates to antiviral compounds for hepatitis C viruses (HCVs) and nontoxic pharmacologically-acceptable salts thereof, wherein the compounds are represented by a formula I shown in the description and have good bioavailability, and the compounds have potent inhibiting effects on the all-genotypic HCVs. In the structural formula I, R1, R2, R3 and R4 are independently selected from methyl (-CH3) or deuterated methyl (-CD3); X1, X2, X3, X4 and X5 are separately hydrogen (H) or deuterium (D); and one of the R1, the R2, the R3 and the R4 must be deuterated methyl (-CD3) or one of theX1, the X2, the X3, the X4, and the X5 must be deuterium (D).

PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS

The present disclosure provides processes for the preparation of a compound of formula: which is useful as an antiviral agent. The disclosure also provides compounds that are synthetic intermediates.

ANTIVIRAL COMPOUNDS

The disclosure is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.

CONDENSED IMIDAZOLYLIMIDAZOLES AS ANTIVIRAL COMPOUNDS

The disclosure is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.

ANTIVIRAL COMPOUNDS

The disclosure is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.